146 related articles for article (PubMed ID: 37204613)
1. Rivastigmine Use in the Treatment of Antimuscarinic Delirium.
Greene SC
J Med Toxicol; 2023 Jul; 19(3):284-287. PubMed ID: 37204613
[No Abstract] [Full Text] [Related]
2. Diphenhydramine-Induced Antimuscarinic Delirium Treated with Physostigmine and Transdermal Rivastigmine.
Whitledge JD; Watson CJ; Simpson M; Bakkar A; Boussi L; Scott M; Boyle KL
J Med Toxicol; 2023 Apr; 19(2):219-223. PubMed ID: 36575250
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine for the management of anticholinergic delirium.
Chiew AL; Holford AG; Chan BSH; Isoardi KZ
Clin Toxicol (Phila); 2024 Feb; 62(2):82-87. PubMed ID: 38465631
[TBL] [Abstract][Full Text] [Related]
4. Prolonged Antimuscarinic Delirium in a Child Due to Benztropine Exposure Treated With Multiple Doses of Physostigmine.
Thornton SL; Farnaes L; Minns A
Pediatr Emerg Care; 2016 Apr; 32(4):243-5. PubMed ID: 26383155
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication.
Van Kernebeek MW; Ghesquiere M; Vanderbruggen N; Verhoeven E; Hubloue I; Crunelle CL
Clin Toxicol (Phila); 2021 May; 59(5):447-448. PubMed ID: 32960128
[No Abstract] [Full Text] [Related]
6. Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report.
Fratta KA; Ginder M; Haggerty DA
J Emerg Med; 2023 Oct; 65(4):e366-e368. PubMed ID: 37716903
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
Fischer P
J Clin Psychopharmacol; 2001 Feb; 21(1):118. PubMed ID: 11199939
[No Abstract] [Full Text] [Related]
8. Physostigmine for Antimuscarinic Toxicity.
Saadi R; Bohnenberger K
J Emerg Nurs; 2020 Jan; 46(1):126-128. PubMed ID: 31918808
[No Abstract] [Full Text] [Related]
9. Treatment of Anticholinergic Delirium with Oral Rivastigmine: A Case Report.
Karousatos C; Murphy L
J Emerg Med; 2024 May; 66(5):e589-e591. PubMed ID: 38658202
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pediatric antimuscarinic delirium with oral rivastigmine.
Yakey B; Vohra V; Martin A; King AM
Oxf Med Case Reports; 2023 Sep; 2023(9):omad096. PubMed ID: 37771682
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome.
Wang GS; Baker K; Ng P; Janis GC; Leonard J; Mistry RD; Heard K
Clin Toxicol (Phila); 2021 Aug; 59(8):698-704. PubMed ID: 33295809
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological management of anticholinergic delirium - theory, evidence and practice.
Dawson AH; Buckley NA
Br J Clin Pharmacol; 2016 Mar; 81(3):516-24. PubMed ID: 26589572
[TBL] [Abstract][Full Text] [Related]
13. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
[TBL] [Abstract][Full Text] [Related]
14. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center.
Boley SP; Olives TD; Bangh SA; Fahrner S; Cole JB
Clin Toxicol (Phila); 2019 Jan; 57(1):50-55. PubMed ID: 29956570
[TBL] [Abstract][Full Text] [Related]
15. Shortages of agents used to treat antimuscarinic delirium.
Whitledge JD; Soto P; Glowacki KM; Fox ER; Mazer-Amirshahi M
Am J Emerg Med; 2023 May; 67():163-167. PubMed ID: 36893630
[TBL] [Abstract][Full Text] [Related]
16. Physostigmine for Facilitation of Care in Clozapine-Associated Anticholinergic Delirium.
Spring JD; Goldstein BN; Buster M; Mahmoud AA; Hamm B
J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):329-331. PubMed ID: 35260542
[No Abstract] [Full Text] [Related]
17. Physostigmine should be used more readily for antimuscarinic toxicity: PRO.
Dawson A
Br J Clin Pharmacol; 2022 Jan; 88(1):58-60. PubMed ID: 34705298
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.
Yu A; Wu S; Zhang Z; Dening T; Zhao S; Pinner G; Xia J; Yang D
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012494. PubMed ID: 29952000
[TBL] [Abstract][Full Text] [Related]
19. Physostigmine should be used more readily for antimuscarinic toxicity: CON.
Mullins ME
Br J Clin Pharmacol; 2022 Jan; 88(1):61-63. PubMed ID: 34784063
[No Abstract] [Full Text] [Related]
20. A Comparison of Resource Utilization in the Management of Anticholinergic Delirium Between Physostigmine and Nonantidote Therapy.
Boley SP; Stellpflug SJ
Ann Pharmacother; 2019 Oct; 53(10):1026-1032. PubMed ID: 31023063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
